Sorrento Therapeutics Revenue and Competitors

Claim your profile

Location

#9577

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Sorrento Therapeutics's estimated annual revenue is currently $21.2M per year.(i)
  • Sorrento Therapeutics received $150.0M in venture funding in November 2018.
  • Sorrento Therapeutics's estimated revenue per employee is $49,632
  • Sorrento Therapeutics's total funding is $264.4M.

Employee Data

  • Sorrento Therapeutics has 427 Employees.(i)
  • Sorrento Therapeutics grew their employee count by 16% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11830M5400%$2.7B$83B
#2
$1200M106690%$2.4B$8.4B

Sorrento Therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.

keywords:N/A

$264.4M

Total Funding

427

Number of Employees

$21.2M

Revenue (est)

16%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Sorrento Therapeutics News

2022-04-20 - $17.83 Million in Sales Expected for Sorrento Therapeutics ...

Sorrento Therapeutics, Inc, a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory,...

2022-04-19 - Scilex Holding Company, a majority-owned subsidiary of ...

About Sorrento Therapeutics , Inc. Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat...

2022-04-19 - Sorrento Announces FDA Authorization to Proceed with ...

Sorrento Announces FDA Authorization to Proceed with Phase 1 Study of Intravenous STI-9167 (COVISHIELD), a Potent Neutralization Antibody Against Omicron BA.2...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$70.5M42718%$347.4M
#2
$144.5M42816%N/A
#3
$75.8M433N/AN/A
#4
$75M43417%N/A
#5
$79M436N/AN/A

Sorrento Therapeutics Funding

DateAmountRoundLead InvestorsReference
2013-10-28$30.0MUndisclosedArticle
2013-10-31$34.6MUndisclosedAegis Capital CorpArticle
2014-05-15$25.0MUndisclosedAegis Capital CorpArticle
2016-04-12$150.0MUndisclosedAlly Bridge GroupArticle
2016-05-03$10.0MUndisclosedYuhan CorporationArticle
2016-06-14$150.0MUndisclosedMultipleArticle
2016-11-29$75.0MUndisclosedHercules Capital, Inc.Article
2017-04-20$43.5MUndisclosedCantor Fitzgerald & CoArticle
2018-11-09$150.0MUndisclosedOaktree Capital ManagementArticle